Alchemistry
Physics-based relative binding free energy calculation engine
Software · Cloud SaaSCompany source
Company profile
About Insilico Medicine
Insilico Medicine is a clinical-stage biotechnology company pioneering the application of generative artificial intelligence to drug discovery and development. Founded in 2014, the company has built a comprehensive end-to-end AI platform called Pharma.AI that spans target discovery, molecule generation, and clinical trial design. The platform includes specialized tools such as PandaOmics for target identification, Chemistry42 for generative chemistry, Generative Biologics for biomolecule discovery, inClinico for clinical trial prediction, and Science42:DORA, a multi-agent generative research assistant. The company's mission is to extend healthy productive longevity by transforming drug discovery with generative AI, significantly reducing the time and cost to bring life-saving medications to patients. Insilico has successfully advanced multiple AI-discovered drug candidates into clinical trials, including programs for idiopathic pulmonary fibrosis, BRCA-mutated cancer, and various oncology and metabolic diseases. The company has established collaborations with 10 of the top 20 global pharmaceutical companies and has out-licensed several programs to partners including Exelixis and Menarini. Insilico Medicine operates globally with offices in the United States, Greater China, Canada, and the Middle East. The company is publicly listed and backed by leading investors including Warburg Pincus, Qiming Venture Partners, WuXi AppTec, B Capital Group, and others. The company's scientific approach combines deep learning, generative adversarial networks, reinforcement learning, and foundation models to discover novel targets and generate novel molecules with optimized properties.
Company description Insilico Medicine official website
Mission. Our mission is to extend healthy productive longevity for everyone by transforming drug discovery and development with generative artificial intelligence, significantly reducing the time and cost to bring life-saving medications to patients.
Primary marketGenerative AI & Healthcare Infrastructure
Commercial modelCommercial information available on request
Work at Insilico Medicine?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cancer (BRCA-mutant, MTAP deficient, ER+/HER2- breast cancer, mesothelioma, solid tumors)
- Chronic Kidney Disease (CKD)
- COVID-19 and coronavirus infections
- Fibrotic diseases (lung and kidney)
- Inflammatory Bowel Disease (IBD)
- Multiple sclerosis
- Neurodegenerative diseases
- Neuropathic pain
- Parkinson's disease
- Psoriasis
Who it serves
- Academic partners
- Biotech companies
- Pharmaceutical companies
- Research institutions
Deployment & integration
Cloud Saas · On Premise · Other deployment with recorded integration context.
Geographic context
MarketsCanada · Global · Greater China (Hong Kong, Shanghai) · Middle East (Abu Dhabi) · United States
Company sourceOfficial website
Company milestones
Platform expansion
Named most innovative biotechnology company in the world 2024. Multiple drug candidates advancing to clinical stages. Established global presence across U.S., Greater China, Canada, and Middle East.
Partnerships
Recorded partners
- 10 of the top 20 global pharmaceutical companies (by 2021 sales)
- GlaxoSmithKline (GSK)
- Medicilon
- Top institutions and universities globally
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Chemistry42
Generative AI for small molecule drug design and optimization
Software · Cloud SaaSCompany source
Generative Biologics
AI platform for biologics and antibody design
Software · Cloud SaaSCompany source
inClinico
AI-powered clinical trial outcome prediction platform
Software · Cloud SaaSCompany source
Life Star 2
Automated laboratory operating environment
Platform · On PremiseCompany source
MMAI Gym
Foundation model training and benchmarking platform for drug discovery
Platform · Cloud SaaSCompany source
Nach01
AI-discovered therapeutic program
Other · OtherCompany source
PandaOmics
AI-powered target discovery and disease modeling platform
Software · Cloud SaaSCompany source
PandaOmics Box
Packaged version of PandaOmics for target discovery
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Toward autonomous science with agentic artificial intelligence.Cell · Sep 17, 2026
An open benchmark and language models for AI in aging biology.Cell · Sep 17, 2026
Control theory of aging and longevity for gerotherapeutic drug discovery: state space, vector fields, modalities, safety, and the minimum safe cost of functional restoration.Aging · Sep 16, 2026
Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads.Journal of medicinal chemistry · Sep 10, 2026
Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment.Nature biotechnology · Sep 7, 2026
Toward First-in-Class Brain PET Tracers for Imaging TDP-43 Pathology.Chemical & biomedical imaging · Aug 24, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Time and cost reduction
Significantly reducing the time and cost to bring life-saving medications to patients through AI-driven drug discovery
Pipeline advancement
Leading AIDD pipeline progress with multiple programs in Phase II, Phase I, and IND-enabling stages
10 of top 20 global pharmaceutical companies
Collaboration on AI-driven drug discovery using Pharma.AI platform
Established collaborations with 10 of the top 20 global pharmaceutical companies by 2021 sales
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Feng Ren
co-CEO, CSO, Head of Drug R&D
Stephanie Tsang
Senior EA to Co-CEO & President | Head of Operations, Office of Alex Zhavoronkov, PhD (Co-CEO)
Jacki Russell
Founder of Anti-Ageing & Wellness
Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP
Vice President Clinical Development
Luoheng Qin
Vice President of Chemistry
Halle Zhang
Vice President, Clinical Development - Oncology
Leah Liu
Global Head of Capital Markets, VP
谢亦谦
BD associate director
06 · Company updates
Updates from Insilico Medicine
Recent articles published on Insilico Medicine's official website.
Insilico Medicine is Using Generative AI to Design New Drugs for Rare Diseases
Read on Insilico MedicineModel Validation: Automated Train–Test Leakage Audit
Read on Insilico MedicineEnd-to-End AI-Driven Design of a First-in-Class PKMYT1 PROTAC Using Chemistry42
Read on Insilico MedicinePROTAC decomposition: Multi-stage linker extraction
Read on Insilico MedicineScience42: DORA.Introducing the Draft Outline Research Assistant workflow
Read on Insilico Medicine07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
AI Slashes Drug Discovery Time by 75% as UAE Lab Unveils Third Cancer Candidate This Year
Insilico Medicine's artificial intelligence platforms have identified novel blood cancer molecules in 12-18 months, a process that traditionally takes up to four years, marking the company's third major therapeutic announcement in six months.
Drug Discovery & Research · Oct 7, 2026
AI-Designed Drug Reaches Landmark Phase III Trial for Fatal Lung Disease
Insilico Medicine's rentosertib becomes the first AI-developed therapeutic to enter late-stage testing for idiopathic pulmonary fibrosis, a condition with few treatment options and a median survival of just 3-4 years.
Drug Discovery & Research · Sep 28, 2026
The First Fully AI-Designed Drug Reaches Phase 3 Trials—And Its Maker Is Already Profitable
Insilico Medicine's rentosertib marks a watershed moment for artificial intelligence in pharmaceutical development, advancing to large-scale human testing while the company reports $35.5 million in net profit.
Drug Discovery & Research · Sep 19, 2026
Machine Learning Cracks the Mitochondrial Code: Five New Drug Targets Emerge for Alzheimer's Treatment
Insilico Medicine's AI platform identifies blood-detectable biomarkers and novel therapeutic pathways by analyzing mitochondrial dysfunction across multiple neurodegenerative diseases.
Drug Discovery & Research · Sep 8, 2026
The Patent Paradox Threatening Billions in AI-Discovered Drugs
As artificial intelligence designs novel therapeutics with minimal human input, U.S. patent law's human-inventor requirement is creating legal uncertainty that could invalidate exclusivity rights for an entire generation of AI-developed medicines.
Drug Discovery & Research · Aug 22, 2026
Drug Discovery's New Speed Limit: How AI Slashed a Decade-Long Process to 18 Months
Insilico Medicine's breakthrough pulmonary fibrosis candidate reached Phase 2 trials in record time, forcing clinical operators to rethink procurement, trial partnerships, and patient engagement strategies.
Drug Discovery & Research · Aug 14, 2026
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Generative AI & Healthcare Infrastructure
Companies providing generative AI platforms, large language models (LLMs), foundation models, or broad AI infrastructure specifically designed for healthcare applications. These companies serve multiple clinical use cases across the health system rather than focusing on a single clinical application or disease area.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.